Karyopharm Therapeutics Inc (OQ:KPTI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 85 Wells Ave
Tel: N/A
Website: https://karyopharm.com
IR: See website
Key People
Sharon Shacham
President, Chief Scientific Officer
Michael G. Kauffman
Co-Founder, Chief Executive Officer and Director
Michael P. Mason
Chief Financial Officer, Senior Vice President, Treasurer
Christopher B. Primiano
Executive Vice President, Chief Business Officer, General Counsel and Secretary
Perry Monaco
Senior Vice President of Sales
Ran Frenkel
Chief Development Operations Officer
Business Overview
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.
Financial Overview
For the nine months ended 30 September 2019, Karyopharm Therapeutics Inc revenues decreased 24% to $22.8M. Net loss increased 26% to $150.9M. Revenues reflect License and other revenue decrease of 67% to $10M. Higher net loss reflects General and Administrative increase from $30.1M to $77M (expense), Other income (expense) increase of 80% to $36K (expense).
Employees: 332 as of Feb 15, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $787.93M as of Sep 30, 2019
Annual revenue (TTM): $23.00M as of Sep 30, 2019
EBITDA (TTM): -$202.54M as of Sep 30, 2019
Net annual income (TTM): -$209.15M as of Sep 30, 2019
Free cash flow (TTM): -$200.75M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 62,790,043 as of Oct 29, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization